HEALTH● LOWJul 9 · Jul 9, 2026, 9:30 PM
Bausch + Lomb abandons glaucoma drops after phase 2 failure
Seeking Alpha Tech
Bausch + Lomb has discontinued its glaucoma drops development project. This decision follows the failure of the drug during its phase 2 trials.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH16m agoNew labor rule to shed light on PBM payments: WSJSeeking Alpha TechHEALTH23m agoIndonesia weighs tighter ketamine controls amid surge in seizures, abuse casesSouth China Morning PostHEALTH50m agoDraftKings CEO Jason Robins says parents should talk with kids about gambling addictionCNBCHEALTH55m agoClimate change: Scientists call for declaration of 'global health emergency' after new reportLe Monde [en]